Here are a few brief analogies for Fulcrum Therapeutics (FULC):

• An emerging Vertex Pharmaceuticals for other rare genetic diseases.

• A specialized biotech developing treatments for genetic disorders, similar to a focused, early-stage Biogen.

• losmapimod: A small molecule in development for the treatment of facioscapulohumeral muscular dystrophy.
• FTX-6058: An investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies.

Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company focused on the research and development of drug candidates. As such, it does not currently have approved products for commercial sale directly to individual patients or to healthcare providers like hospitals and pharmacies.

Instead, the company's revenue generation at this stage primarily comes from collaboration and licensing agreements with other pharmaceutical companies. Based on the provided background information, its major collaboration partners, which can be considered its primary "customers" or sources of revenue through partnership, are:

• Acceleron Pharma Inc. (This company was acquired by Merck & Co., Inc. (NYSE: MRK). The collaboration agreement would now be associated with Merck.)
• MyoKardia, Inc. (This company was acquired by Bristol Myers Squibb Company (NYSE: BMY). The collaboration agreement would now be associated with Bristol Myers Squibb.)

These companies entered into research, discovery, and strategic collaboration agreements with Fulcrum Therapeutics to develop and potentially commercialize novel therapies.

Alex C. Sapir
Chief Executive Officer and President

Mr. Sapir is an industry veteran with over two decades of experience in the biopharmaceutical industry. He most recently served as CEO of ReViral Ltd, which was acquired by Pfizer in 2022. Prior to ReViral, he was President and CEO at Dova Pharmaceuticals, where he led its transformation from a private, pre-commercial company to a publicly traded biotech company that was later acquired by Sobi, Inc. Earlier in his career, Mr. Sapir was the Executive Vice President for Marketing and Sales at United Therapeutics and held commercial positions of increasing responsibility at GSK.

Alan A. Musso
Chief Financial Officer

Mr. Musso joined Fulcrum in August 2023 as Chief Financial Officer. Prior to Fulcrum, he served as CFO of ReViral, which was acquired by Pfizer in 2022. Previously, he was the Chief Financial Officer and Treasurer at Peloton Therapeutics Inc., where he secured a $150 million mezzanine financing and prepared the company for a NASDAQ IPO until it was acquired by Merck & Co. Mr. Musso also served as CFO and Treasurer of other biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals.

Curtis Oltmans, JD
General Counsel

Mr. Oltmans joined Fulcrum as General Counsel in November 2020 and brings over 25 years of experience in corporate law. He previously served as Executive Vice President, General Counsel, and Corporate Secretary at Array BioPharma Inc., overseeing all legal, corporate governance, patent, and compliance matters, prior to its acquisition by Pfizer. Mr. Oltmans also served as Corporate Vice President and General Counsel for Novo Nordisk, Inc., North America, and Assistant General Counsel for Eli Lilly and Company.

Lisa Percival
Chief Regulatory & Quality Assurance Officer

Ms. Percival joined Fulcrum in October 2025 as Chief Regulatory & Quality Assurance Officer. Prior to Fulcrum, she served as Senior Vice President, Head of Regulatory at Belenos Bio and Vividion Therapeutics. She also held roles as an entrepreneur in residence, regulatory strategy for Atlas Venture stealth companies, and as Senior Vice President, Regulatory Affairs for Third Harmonic Bio.

Iain Fraser, MBChB, D. Phil.
Senior Vice President, Early Development

Dr. Fraser was named Senior Vice President, Early Development in March 2024, having previously served as Interim Chief Medical Officer from March 2023 to March 2024. He brings over two decades of experience advancing therapies through early- and late-stage development with expertise in clinical development and regulatory affairs. He most recently served as Vice President and Clinical Fellow at AlloVir, an Elevate Bio Company.

The key risks for Fulcrum Therapeutics (FULC) primarily revolve around the inherent challenges of drug development and commercialization in the biopharmaceutical industry.

1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Fulcrum Therapeutics' success is heavily dependent on its ability to successfully develop and obtain regulatory approval for its product candidates. The discontinuation of their losmapimod program for facioscapulohumeral muscular dystrophy (FSHD) in September 2024, following its failure to meet the primary endpoint in a Phase 3 trial, highlights this significant risk. Their lead remaining candidate, pociredir (formerly FTX-6058) for sickle cell disease, previously faced a full clinical hold by the U.S. Food and Drug Administration (FDA) in February 2023 due to concerns about potential hematological malignancies observed with other polycomb repressive complex 2 (PRC2) inhibitors. Although the clinical hold was lifted in August 2023, the company was requested to further define the patient population where the benefits of pociredir outweigh potential risks, indicating ongoing regulatory scrutiny and the potential for future challenges in demonstrating a favorable benefit-risk profile and securing approval.

2. Intellectual Property Protection: The ability to obtain, maintain, and protect intellectual property rights, particularly patents, for its drug candidates is crucial for Fulcrum Therapeutics. Without robust intellectual property protection, the company's significant investment in research and development could be undermined by competitors.

3. Need for Additional Capital: Developing drugs through clinical trials is a capital-intensive process. As a clinical-stage company with no commercialized products generating revenue, Fulcrum Therapeutics is reliant on its existing cash reserves and its ability to raise substantial additional capital to fund its ongoing and future research and development activities, including clinical trials. While the company has indicated a cash runway into 2029, the high costs associated with drug development, coupled with potential setbacks, could necessitate further financing, which may not always be available on favorable terms.

The rapid advancement and growing pipeline of gene therapy and gene-editing technologies for genetically defined diseases pose a significant emerging threat to Fulcrum Therapeutics.

For conditions like sickle cell disease and beta-thalassemia, where Fulcrum's FTX-6058 is an investigational oral fetal hemoglobin inducer, several gene-editing therapies (e.g., Beam Therapeutics' BEAM-101 and Editas Medicine's EDIT-301) are actively progressing through clinical trials. These emerging therapies aim to offer potentially curative, one-time treatments by directly correcting underlying genetic defects, representing a paradigm shift from chronic small molecule management.

This transformative potential of gene therapy and gene editing, which seeks to provide definitive therapeutic options, could fundamentally diminish the long-term market opportunity and clinical relevance for Fulcrum's small molecule product candidates targeting these diseases.

Similarly, for facioscapulohumeral muscular dystrophy (FSHD), where Fulcrum's losmapimod is in development, gene therapies (e.g., Atamyo Therapeutics' ATA-100) and RNA therapeutics (e.g., Avidity Biosciences' AOC 1027) are also progressing through clinical development. While currently in earlier stages, these modalities represent an emerging future for FSHD treatment that could offer more profound and lasting effects compared to small molecule approaches, potentially rendering such approaches less competitive over time.

Fulcrum Therapeutics (symbol: FULC) operates in the addressable markets for Facioscapulohumeral Muscular Dystrophy (FSHD), Sickle Cell Disease, and Beta-thalassemia.

Losmapimod (Facioscapulohumeral Muscular Dystrophy - FSHD)

• The global Facioscapulohumeral Muscular Dystrophy (FSHD) market was valued at approximately USD 210 million in 2024 and is projected to reach USD 482 million by 2034, at a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period (2025-2034).
• In the seven major markets (7MM), which include the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, the FSHD market reached a value of USD 32.2 million in 2024. This market is expected to reach USD 61.4 million by 2035, exhibiting a CAGR of 6.12% during 2025-2035.
• The United States accounts for the largest market share (around 80%) of the FSHD market within the 7MM.

FTX-6058 (Sickle Cell Disease and Beta-thalassemia)

Sickle Cell Disease

• The global sickle cell disease treatment market size was estimated at USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030, growing at a CAGR of 15.7% from 2024 to 2030.
• Another estimate places the global sickle cell disease treatment market size at USD 3.94 billion in 2025, projected to reach USD 20.47 billion by 2034, exhibiting a CAGR of 20.10% from 2026 to 2034.
• In the U.S., the sickle cell disease treatment market generated a revenue of USD 951.7 million in 2023 and is expected to reach USD 2,401.9 million by 2030.
• The U.S. sickle cell disease treatment market size was valued at USD 1.44 billion in 2022 and is projected to grow at a CAGR of 17.3% during the forecast period.

Beta-thalassemia

• The beta thalassemia market in the United States was valued at approximately USD 358 million in 2023 and is projected to expand significantly by 2034.
• The U.S. Beta Thalassemia Market is estimated at USD 0.67 billion in 2024 and is projected to reach approximately USD 1.02 billion by 2030, with a CAGR of 7.4%.
• Across the top 7 markets (US, EU4, UK, and Japan), the beta thalassemia market reached a value of USD 368.7 million in 2024 and is expected to reach USD 901.7 million by 2035, exhibiting a CAGR of 8.48% during 2025-2035.

Fulcrum Therapeutics (FULC) is expected to drive future revenue growth over the next two to three years primarily through the advancement and potential commercialization of its lead product candidates and strategic collaborations:

1. Commercialization of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) in the U.S. Fulcrum Therapeutics retains full U.S. commercialization rights for losmapimod, its investigational oral small molecule for the treatment of FSHD. The company anticipates reporting topline data from the global Phase 3 REACH clinical trial in the fourth quarter of 2024. Following positive Phase 3 data, Fulcrum and its partner Sanofi plan to submit marketing applications in the U.S., Europe, Japan, and other geographies, positioning losmapimod for potential market entry and revenue generation in the U.S. within the next 2-3 years.
2. Milestone Payments and Royalties from Sanofi Collaboration for Losmapimod (ex-U.S.). In May 2024, Fulcrum entered a collaboration and license agreement with Sanofi, granting Sanofi exclusive commercialization rights for losmapimod outside the U.S. Under this agreement, Fulcrum received an upfront payment of $80 million and is eligible to receive up to an additional $975 million in specified regulatory and sales-based milestones, along with tiered escalating royalties on annual net sales of losmapimod outside the U.S. These milestone payments and future royalties are expected to contribute significantly to Fulcrum's revenue as losmapimod progresses through regulatory approvals and commercialization in international markets.
3. Advancement and Potential Commercialization of Pociredir (FTX-6058) for Sickle Cell Disease. Fulcrum's investigational oral fetal hemoglobin inducer, pociredir (FTX-6058), is being developed for the treatment of sickle cell disease (SCD). The company has reported promising 12-week outcomes from its Phase 1b PIONEER trial, demonstrating significant increases in fetal hemoglobin levels. Analysts project substantial revenue growth for Fulcrum, estimating $560 million by 2028, primarily driven by the anticipated market opportunities in SCD due to a lack of existing treatment options. Fulcrum is progressing towards a Phase 3 trial for pociredir in the second half of 2026, which, if successful, could lead to its eventual commercialization and significant revenue streams.

Share Issuance

• In December 2025, Fulcrum Therapeutics completed a public offering of common stock and pre-funded warrants, generating net proceeds of $164.2 million.
• The company's common stock issuance totaled $186.53 million in 2021, $84.32 million in 2022, and $118.12 million in 2023.
• Shares outstanding increased to 67 million in Q4 2025, marking a 23.0% increase from the prior quarter.

Inbound Investments

• Fulcrum Therapeutics received net proceeds of $164.2 million from a public offering of its common stock and pre-funded warrants in December 2025.
• As of December 31, 2025, the company's cash, cash equivalents, and marketable securities stood at $352.3 million, extending its cash runway into 2029.

Capital Expenditures

• Capital expenditures were $0.159 million in Q4 2025.
• Annual capital expenditures were approximately $1.71 million in 2021, $1.96 million in 2022, $0.51 million in 2023, $0.28 million in 2024, and $0.39 million in 2025.
• These expenditures are primarily focused on funding long-term assets and infrastructure.